Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome

The FDA approval last Friday of Novo Nordisk’s Rybelsus as the first orally-active GLP-1 agonist is only the first challenge facing the company as it pursues its blockbuster sales targets for the diabetes drug.

The next big question is the price of Rybelsus (semaglutide), and whether it will be an obstacle to take-up of the drug in the increasingly cost-conscious US diabetes market.